Drug discovery specialist Synt:em completes $4.4 million financing Venture capital firms provide finance for Synt:em's growth plans Nîmes, December 17, 1997--Synt:em announces today the completion of a new round of financing to support the next stage of company growth. The company now has the support of two international venture firms, Apax Partners and Banexi Ventures, both of which have significant experience in biotechnology and healthcare. New investments of approximately $3.4 million, bring the capital to something over $4.25 million. Synt:em has also obtained a more than $1 million innovation grant from French government agency, ANVAR, which will be reimbursed when the project is successfully completed.. The new funds will be used in particular for the development of Synt:em's proprietary Pep:Trans technology. Pep:Trans is based on new peptide-derived vectors able to cross membranes. This allows therapeutic molecules to be delivered to intracellular targets with greatly increased efficacy. Pep:Trans is expected to overcome a common drug discovery problem where molecules are found to be extremely effective in vitro but which fail in vivo. This is due in particular to low bioavailability (the length of time the molecule remains in human tissue) or inability to pass through biological membranes. Using Pep:Trans will both increase the effectiveness of drug delivery and allow the administration of smaller doses. Pep:Trans takes full advantage of Synt:em's "In Silico Screening", a technology platform based on chemical synthesis and molecular modelling that has been under development at Synt:em for more than two years. Current shareholders are now: Apax Partners, Banexi, investors from earlier rounds (Soridec, Sofimac, Sofilaro, Mistral Investissement), who also participated in the capital increase, private investors ("angels") and management. "Apax Partners and Banexi bring the company additional international experience in analysing the biotechnology market, offering an outside perspective on Synt:em's strategy and facilitating connections or partnerships with other companies in the business," said Michel Kaczorek, president and ceo of Synt:em. "In addition, they have approved a capital structure that retains management incentives by allowing the latter to conserve a significant part of the capital." "We are very pleased to support the development of one of the most innovative companies in drug discovery," said Dr Laurent Ganem, Partner at Apax Partners, and President of the Conseil de Surveillance of Syntem. "The current molecular modelling capabilities of Synt:em are quite impressive, and we are much excited about the intracellular drug delivery research program that is being carried out, for which we believe the products will have broad application." "Synt:em has built an outstanding drug discovery platform with an unprecedented combination of skills and which is already validated by several pharmaceutical contracts," said Sophie Pierrin-Lépinard, Banexi Ventures Partner. "We are very proud to share this exciting new step of the company. Synt:em fits perfectly with our current porfolio." About Apax... Apax Partners provides equity funding and corporate finance advice to entrepreneurial businesses internationally. The Group manages nearly $3 billion of private equity funds, over $400 million of which is managed in France, and invests across the spectrum of early stage, expansion capital, management buy-out and buy-in opportunities out of thirteen offices. Biotechnology and Health Care are privileged fields of investment for Apax Partners. Examples of investments completed in Europe and in the United States include: Effik, IDM, NicOx, PPL Therapeutics, Scotia, Creative Biomolecules. Cytyc. About Banexi... Banexi Ventures is the venture capital arm of Banexi, a fully owned subsidiary of BNP (Banque Nationale de Paris). Banexi Group has invested 525 million French francs ($88 million) in 180 venture capital deals over the last 14 years, in three main areas : Information technology, semiconductors and Life Sciences. Examples of investments based on technology platforms: Biovector Therapeutics (drug delivery), IDM (cell therapy), Neurotech (cell-based gene therapy). About Synt:em Synt:em specialises in the discovery of new therapeutic molecules using state-of-the-art tools in the field of structural biology, and molecular modelling and synthesis. Since it was founded in 1995, the company has focussed on two complementary technologies: 1. Research tools and services, particularly in peptide synthesis. 2. Contract research for the design and synthesis of new therapeutic molecules. Synt:em is already active in international markets, particularly in the USA. It is located close to Montpellier, giving it easy access to one of the world's leading centres of peptide expertise. Synt:em currently employs 16 people, including 12 doctors of science and engineers. The company can count on the know-how and experience of more than 80 researchers through a number of partnership agreements signed with leading laboratories in the fields of cellular and structural biology, modelling and pharmacology. Synt:em's revenues in its first accounting period to 31 December 1996 were 2.45 million francs (about $410,000). Forecast revenues for 1997 are 5 million francs ($830,000). The company continues actively to seek partnerships with industry to extend the applicability of its technology to other therapeutic areas. Brighton Business Centre 221 bd Raspail 95 Ditchling Road 75014 Paris Brighton BN1 4ST France England Tel: +44-1273 675100 Tel: +33-1 43 22 79 56 Fax: +44-1273 675400 Fax: +33-1 43 20 90 92 email: allo@ala.com OR ala-france@ala.com (For ALA Paris office only) OR ala@pavilion.co.uk (For ALA UK office only) INTERNATIONAL TECHNOLOGY MARKETS STRATEGY & COMMUNICATIONS chemweb: A list for Chemical Applications of the Internet. To post to list: mailto:chemweb@ic.ac.uk Archived as: http://www.lists.ic.ac.uk/hypermail/chemweb/ To (un)subscribe, mailto:majordomo@ic.ac.uk the following message; (un)subscribe chemweb List coordinator, Henry Rzepa (mailto:rzepa@ic.ac.uk)